Video Experimental Relacionado
Updated: Sep 10, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
Monoterapia con Upadacitinib para el tratamiento de Pyoderma Gangrenosum
Mohamad R Taha1, Harrison P Nguyen2, Stephen K Tyring2,3
1College of Medicine, Texas A&M University Health Science Center, Bryan, Texas.
American journal of medicine open
|August 22, 2025
Resumen
Pyoderma gangrenosum (PG) es una condición dolorosa de la úlcera de la piel. Este estudio muestra que el upadacitinib, un inhibidor de Janus kinase (JAK), trató con éxito a pacientes con PG, ofreciendo una nueva opción terapéutica.
Área de la Ciencia:
- Dermatología
- Inmunología
- Farmacología
Sus antecedentes:
- Pyoderma gangrenosum (PG) es una dermatosis neutrófila ulcerosa poco frecuente.
- Los tratamientos actuales carecen de estandarización y a menudo resultan en recurrencia.
- La vía Janus kinase (JAK) / transductor de señal y activador de la transcripción (STAT) está implicada en la patogénesis de PG.
Objetivo del estudio:
- Evaluar la eficacia del upadacitinib, un inhibidor selectivo de la JAK, en el tratamiento de la pioderma gangrenosa.
Principales métodos:
- Este estudio describe una serie de casos de pacientes con pioderma gangrenoso.
- Los pacientes fueron tratados con upadacitinib, un inhibidor selectivo de la Janus quinasa (JAK).
Principales resultados:
- Upadacitinib demostró un tratamiento exitoso de la pioderma gangrenosa en esta serie de casos.
- El tratamiento condujo a la curación de úlceras progresivas y dolorosas.
Conclusiones:
- La inhibición selectiva de JAK con upadacitinib es un tratamiento prometedor para la pioderma gangrenosa.
- Dirigirse a la vía JAK/STAT ofrece una estrategia terapéutica potencial para esta condición.
Videos de Conceptos Relacionados
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
252
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
252
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
40
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
40
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202